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Increasing comorbidity is associated with
worsening physical function and pain after
primary total knee arthroplasty
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Abstract
Background: Previous studies suggested that pre-operative comorbidity was a risk factor for worse outcomes after
TKA. To our knowledge, studies have not examined whether postoperative changes in comorbidity impact pain and
function outcomes longitudinally. Our objective was to examine if increasing comorbidity postoperatively is
associated with worsening physical function and pain after primary total knee arthroplasty (TKA).
Methods: We performed a retrospective chart review of veterans who had completed Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) and Short Form-36 (SF36) surveys at regular intervals after
primary TKA. Comorbidity was assessed using a variety of scales: validated Charlson comorbidity index score, and a
novel Arthroplasty Comorbidity Severity Index score (Including medical index, local musculoskeletal index [including
lower extremity and spine] and TKA-related index subscales; higher scores are worse ), at multiple time-points post-
TKA. We used mixed model linear regression to examine the association of worsening comorbidity post-TKA with
change in WOMAC and SF-36 scores in the subsequent follow-up periods, controlling for age, length of follow-up,
and repeated observations.
Results: The study cohort consisted of 124 patients with a mean age of 71.7 years (range 58.6–89.2, standard
deviation (SD) 6.9) followed for a mean of 4.9 years post-operatively (range 1.3–11.4; SD 2.8). We found that post-
operative worsening of the Charlson Index score was significantly associated with worsening SF-36 Physical
Function (PF) (beta coefficient (ß) = -0.07; p < 0.0001), SF-36 Bodily Pain (BP) (ß = -0.06; p = 0.002), and WOMAC PF
subscale (ß = 0.08; p < 0.001; higher scores are worse) scores, in the subsequent periods. Worsening novel medical
index subscale scores were significantly associated with worsening SF-36 PF scores (ß = -0.03; p = 0.002), SF-36 BP (ß
= -0.04; p < 0.001) and showed a non-significant trend for worse WOMAC PF scores (ß = 0.02; p = 0.11) subsequently.
Local musculoskeletal index subscale scores were significantly associated with worsening SF-36 PF (ß = -0.05; p = 0.
001), SF-36 BP (ß = -0.04; p = 0.03) and WOMAC PF (ß = 0.06; p = 0.01) subsequently. None of the novel index
subscale scores were significantly associated with WOMAC pain scores. TKA complications, as assessed by TKA-
related index subscale, were not significantly associated with SF-36 or WOMAC domain scores.
Conclusions: Increasing Charlson index as well as novel medical and local musculoskeletal index subscale scores
(from novel Arthroplasty Comorbidity Severity Index) post-TKA correlated with subsequent worsening of physical
function and pain outcomes post-TKA. Further studies should examine which comorbidity management could have
the greatest impact on these outcomes.
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Background
Over 719,000 total knee arthroplasties (TKAs) were
performed in 2010 in the United States [1] and the
annual incidence of TKA is expected to increase 7-
fold from 2005 to 2030 and exceed 3.5 million annu-
ally by 2030 [2]. TKA is associated with impressive
gains in the quality of life (QOL) of patients [3]. The
benefit achieved with TKA, however, is not universal,
nor is it always sustained [4]. Understanding the fac-
tors that influence arthroplasty outcomes will allow
for better patient selection, provide patients with
more realistic expectations, and optimize the proce-
dure’s benefits.
Comorbid conditions may contribute to variation
in post-arthroplasty outcome. This is particularly
relevant due to the increasing obesity and longevity
of the population, which is likely to lead to higher
comorbidity in joint arthroplasty recipients. Out-
comes, which have thus far been studied in relation
to comorbidity, include the length of hospital stay,
post-operative complications, short-term readmission
and mortality, and short-term pain and physical
function. Although it is the perception of both refer-
ring physicians and surgeons that higher comorbidity
burden relates to worse outcome [5], the literature
on this subject is limited and the study results are
contradictory.
Higher comorbidity was associated with worse out-
come in some studies [6–12] but not in others [13–17].
A recent review of the effect of comorbidity on arthro-
plasty outcomes concluded “…the overall impact appears
to be small” [18]. However, only two of the above-
mentioned studies that we found [13, 15] were included
in this recent review. The negative and positive studies
differed in the confounders adjusted for and the out-
come measures, which might explain some of the differ-
ences noted between studies.
In addition, most TKA studies have examined out-
comes in relation to baseline preoperative comorbidity
rather than the change in comorbidity with time postop-
eratively. A recent paper by Gandhi et al. found that
baseline comorbidity, as measured by the Cumulative Ill-
ness Rating Scale (CIRS) index, negatively impacted SF-
36 Physical Function and Role Physical scores at a mean
of 3 years post-arthroplasty [7]. We were interested in
assessing whether overall comorbidity, changing
through time in the postoperative period, is associated
with a decline in function and worse pain out-
comes after TKA. In this study, we examined the rela-
tionship of the post-operative change in comorbidity
with the change in SF-36 and WOMAC physical func-
tion and pain scores in the subsequent post-TKA
periods. To our knowledge, none of the previous stud-
ies have addressed this question.
Methods
Study population
We performed a retrospective analysis of prospectively
collected data, by additionally performing a detailed
chart review of post-TKA patients at the Minneapolis
Veterans Administration (VA) Medical Center. The In-
stitutional Review Board (IRB) at the Minneapolis VA
approved the study. We included patients from three
studies in primary TKA populations at our medical
center, since all three studies collected prospective inter-
mediate to long-term pain and function outcome data
using Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) or Short Form-36
(SF36) or both, i.e., outcomes of interest for our study.
The patients included in this study were each enrolled in
either a randomized study comparing mobile-bearing
and fixed-bearing cruciate-substituting TKA (SF-36 and
WOMAC) [19], a randomized study comparing all-
polyethylene versus metal-backed components in TKA
(SF-36) [20], or a cohort study evaluating periprosthetic
bone density surrounding tantalum tibial implants in
TKA (SF-36 and WOMAC) [21]. Inclusion and exclu-
sion criteria for each study that provided data are
detailed in Additional file 1. The patients in each study
had completed either both SF-36 and WOMAC surveys,
or WOMAC surveys alone, at regular intervals before
and approximately every year after their surgery, and
had intermediate to long-term follow-up lasting an aver-
age of more than 4 years. We included these patients,
since patients had completed validated outcomes (main
study outcomes), and had a reasonable follow-up.
Data extraction methods
Using a standardized data extraction form, one trained
physician (MH) blinded to the patients’ outcome scores
(SF-36 and WOMAC) extracted data from both paper
and electronic medical records at the Minneapolis
Veterans Affairs (VA) Medical Center. All outpatient
and inpatient notes were reviewed from each chart’s in-
ception. All patients obtained their primary care at this
medical center or, rarely, at other electronically access-
ible VA hospitals/clinics. No patients were excluded due
to non-availability of records.
Data were organized into sequential periods defined by
the interval between surveys, by providing dates for
these periods to the abstractor (MH). Clinical data were
abstracted starting with the baseline post-operative
survey, which was completed 6–12 months after index
primary TKA. Sequential periods were of usually 12–
20 month duration. Patient demographics (age and gen-
der), date of primary TKA and comorbidities were
abstracted. After the completion of data abstrac-
tion, these data were merged with previously collected
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WOMAC and SF-36 scores at patient level and by each
period of interest, for statistical analyses.
Predictors and their definitions
Comorbidity was measured using four measures
(Charlson index and three subscale indices of a novel
scale) and data were collected on comorbidities for
each interval to allow calculation of score for all four
comorbidity measures for each interval.
The Charlson index is a weighted scale containing 17
comorbidities expressed as a sum, which has been
validated in in- and out-patient settings and widely used
for comorbidity adjustment in the medical literature (see
Additional file 2) [22, 23]. We developed an alternate
novel Minnesota Arthroplasty Comorbidity Index with 3
subscale indices to understand the impact of comorbidity
on function and pain outcomes for two reasons: (1)
Charlson index was initially designed to predict mortality
and has comorbidities more applicable to inpatients than
outpatients and most post-TKA patients are outpatients;
and (2) local musculoskeletal comorbidity is likely to im-
pact pain and function after TKA differently than a medical
comorbidity and this is not captured in the Charlson index.
We calculated a novel medical/surgical comorbidity
severity score, the Minnesota Arthroplasty Comorbidity
severity Index (MACI), which measured a greater variety
of comorbidities and a more granular categorization of
disease severity than the Charlson index (Additional file
3). Comorbidities were divided into three subscales:
“Medical index” that included conditions such as dia-
betes, heart disease, cancer etc., conditions common in
patients undergoing TKA(range, 0-47); “Local musculo-
skeletal index”, which comprised any lower extremity,
hip, or spine morbidity (range, 0-10); and “TKA-related
index”, which comprised of any adverse event related to
their index TKA, including loosening, infection, revision
etc. (range, 0-2) (Additional file 3). For each of these
measures of comorbidity, we designed a severity scoring
system; mild, moderate, severe and very severe categor-
ies were scored as 1, 1.5, 2 and 2.5, respectively. This
scoring system was based either on specialty- or society-
approved guidelines, such as the Kidney Disease Out-
comes Quality Initiative (KDOQI) definitions of chronic
kidney disease [24], or in their absence, clinical judgment
of expert consultants in each specialty (cardiologist, endo-
crinologist, nephrologist, rheumatologist, orthopedic sur-
geon, gastroenterologist etc.). The three-component/
subscale scores of our novel medical/surgical comor-
bidity severity index scale, “medical” (range, 0-47);,
“local musculoskeletal” (range, 0-10); and “TKA-re-
lated”, (range, 0-2); were the predictors of interest. In
the case of missing data, values were carried forward
from the previous period/interval.
Outcomes of interest
The SF-36 and WOMAC scores were evaluated from a
6–12 month post-TKA baseline for the first post-TKA
time-point and later time-points for subsequent visits.
This baseline was chosen since most of the benefit in
pain and function in patients undergoing TKA is
achieved by 6–12 months post-operatively [7, 25]. Our
study objective was to examine the effect of changing
comorbidity post-operatively on subsequent pain and
function scores post-TKA, and therefore, we included
post-TKA scores as the baseline scores for our study.
The WOMAC is a widely-used self-administered pain
and functional ability scale for patients with lower-
extremity osteoarthritis (OA) [26], validated in TKA pa-
tients [27]. It assesses pain, physical function, and stiff-
ness, and asks patients about pain or difficulty doing
various daily activities, rated on a five-point scale from
“none” to “extreme”. Scores for each subscale and total
scores were calculated as 0–100 scale; higher scores in-
dicate worse pain, function, and stiffness. We used
WOMAC pain and PF subscales as outcomes. We did
not use WOMAC stiffness subscale as it has low respon-
siveness [28].
The SF-36 is a generic health status measure that is
scored from 0 to100, with 100 being the best score; the
WOMAC is also scored from 0 to100, but 0 is the best
score. The eight subscales are: Bodily pain (BP), Physical
Functioning (PF), Role Physical (RP), Role Emotional
(RE), Social Functioning (SF), Mental Health (MH), Vi-
tality (VT), General Health (GH). We assessed SF-36 PF
and SF-BP, since these subscales capture physical func-
tioning and bodily pain, likely impacted by worsening
comorbidity post-TKA.
Statistical analyses
We examined SF-36 PF, SF-36 BP, WOMAC PF and
WOMAC pain subscale scores as continuous outcome
variables. Model diagnostics including Q-Q plots for re-
siduals and Q-Q plots for random effects were tested.
Based on the inherent skewness evident on these plots,
we used gamma distribution for response with log link
for these continuous variables. We used random inter-
cept gamma generalized linear mixed model with log
link to examine the association of increasing comorbid-
ity score (Charlson and three indices from our novel co-
morbidity measure) with worsening QOL, as measured
by the WOMAC and SF-36 PF and pain subscale scores,
in the subsequent intervals (see above) [29], that con-
trolled for repeated observations. These reported effects
were adjusted for age, baseline respective QOL score
and the length of time from index TKA. We present
beta coefficients (ß) and p-values for these associations.
Sensitivity analyses were performed for these associa-
tions excluding the single female subject.
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Results
Clinical characteristics of the study population
We reviewed the charts of 124 patients (123 male, one
female) who underwent primary TKA between July 1992
and October 2005 and were followed for a mean of
4.9 years post-operatively (range 1.3–11.4 years; SD 2.8)
(Table 1). The average look-back period for preoperative
chart review for the assessment of preoperative comor-
bidity score was 10.5 years (range 2.8–33.8, SD
3.26 years); this score contributed to the immediate
post-operative score.
All patients had completed SF-36 surveys, and 93 of
them had completed WOMAC surveys as well (one in-
cluded study had only SF-36 data). The average age at
time of index surgery was 71.7 years (range 58.6–89.2,
SD 6.9). For 66 patients, this surgery was the only TKA
they had undergone, while the remaining 58 patients
underwent opposite side TKA either prior to or after the
index TKA surgery. This subsequent surgery was taken
into account in our analysis of “Local musculoskeletal”
comorbidities, in which arthroplasties on the opposite
side were noted. We organized data into intervals
defined by the time between sequential WOMAC and
SF-36 surveys in a given patient. The average interval
between these was 1.4 years.
Comorbidity during post-operative follow-up
The average baseline post-operative Charlson score was
0.58 (range 0–3, SD 1.0) (Fig. 1). The average final
Charlson score at study follow-up in interval 5 was 1.85
(range 0–5, SD 1.62; Fig. 1). Of the 124 patients, 78 had
no change in their Charlson score, and 33 of these main-
tained a Charlson score of zero for the entire period of
study. The most common diagnoses were myocardial
infarction (45 patients), diabetes mellitus (41 patients
with 27 without and 14 with end-organ damage),
congestive heart failure (28 patients), cerebrovascular
disease (20 patients with 17 without and 3 with subse-
quent hemiplegia), and chronic pulmonary disease (18
patients). The mean length of each period ranged from 1
to 1.7 years.
The average baseline and post-operative interval 5
novel comorbidity severity index “medical” subscale
scores were 3.7 (range 2–6.5, SD 1.3) and 7.6 (range 2–
16.5, SD 3.6), respectively (Table 1). The mean Charlson
and novel medical comorbidity severity subscale index
scores (medical and local subscales) for each interval are
shown (Fig. 1). Patients had a variable follow-up period
and some completed their last follow-up visit at interval
2, while others at interval 5. The average “local musculo-
skeletal” comorbidity subscale scores were 5.2 at baseline
post-operative (range 2.5–7, SD 1.2) and 1.6 (range 0–3,
SD 1.2) at interval 5 follow-up. The improvement in
local musculoskeletal index subscale scores was largely
attributable to a proportion of patients undergoing op-
posite side TKA, which reduced their high opposite-
knee arthritis scores. Only 16 patients scored points in
the TKA-related Index, for complications ranging from
implant loosening to infection. Seven patients under-
went revision, for a cumulative revision rate of 5.6 % in
this sample.
Pain and Function score worsening during TKA follow-up
Average baseline post-operative WOMAC pain score
was 35 (range 0–100, SD 22.1), which improved to 17.3,
in the first post-operative interval and then gradually
worsened to follow-up score of 26.2 in post-operative
interval 5 (Fig. 2). Mean baseline post-operative
Table 1 Patient characteristics
Overall study Cohort
(n = 124)
Mean ± SD (range)
Cohort with WOMAC and SF-36
data (n = 93)
Mean ± SD (range)
Cohort with SF-36 data
only (n = 31)
Mean ± SD (range)
Age at index surgery, years 71.7 ± 6.9 (58.6–89.2) 72.6 ± 7.4 (59.8–89.2) 69.0 ± 4.3 (58.6–77.6)
Male/total 123/124 92/93 31/31
Dates index TKA performed August 1993- October 2005 April 2001- October 2005 August 1993- August 1996
Duration of post-op follow-up, years 4.9 ± 2.9 (1.3–11.4) 3.5 ± 1.2 (1.5–6.0) 9.2 ± 1.9 (1.3–11.4)
Charlson score at post-TKA baseline 0.58 ± 1.00 (0–3) 0.60 ± 0.89 (0–2) 0.57 ± 1.13 (0–3)
Charlson score at interval 5 post-TKA 1.85 ± 1.54 (0–5) 1.53 ± 1.50 (0–5) 2.7 ± 1.38 (1–5)
Medical subscale score of the novel indexa
at post-TKA baseline (range 0-47)
3.7 ± 1.4 (2–6.5) 3.7 ± 1.03 (2.5–5) 3.8 ± 1.6 (2–6.5)
Medical subscale score of the novel indexa
at interval 5 post-TKA (range 0-47)
7.6 ± 3.6 (2–16.5) 7.1 ± 3.5 (2–13.5) 9.0 ± 3.8 (6–16.5)
Local subscale score of the novel indexa
at post-TKA baseline (range 0-10)
5.2 ± 1.2 (2.5–7) 5.1 ± 0.6 (4.5–6) 5.3 ± 1.5 (2.5–7)
Local subscale score of the novel indexa
at interval 5 post-TKA (range 0-10)
1.6 ± 1.2 (0–3) 1.70 ± 1.3 (0–3) 1.4 ± 1.1 (0–3)
a Novel index, novel medical/surgical comorbidity severity index
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WOMAC PF subscale score was 35.9 (range 0–96, SD
24.7), which improved to 29.4 in post-operative interval
1 and then gradually worsened to a follow-up score of
41 in post-operative interval 5.
Mean SF-36 BP score at post-operative baseline was
44.2 (range 0–90, SD 31.7), did not change in post-
operative interval 1 to 44.7, and then worsened slightly
to 39.6 at the end of follow-up in post-operative interval
5 (range 0–75, SD 21.7) (Fig. 3). Mean SF-36 PF score at
post-operative baseline was 60.7 (range 22–100, SD
26.4), worsened to 54.7 in post-operative interval 1 and
to 43.2 at the end of follow-up in post-operative interval
5 (range 12–100, SD 20.6).
Figure 4 shows that even though some worsening in
WOMAC and SF-36 scores occurred during the postop-
erative follow-up, scores were still meaningfully better at
the interval 5 post-operative, compared to before TKA,
primarily due to a significant initial improvement from
preoperative to immediate post-operative scores.
Association of increasing comorbidity post-TKA with
subsequent QOL worsening
An increasing Charlson index score was significantly asso-
ciated with worsening SF-36 PF (ß = -0.07; p < 0.0001), SF-
36 BP (ß = -0.06; p = 0.002), and WOMAC PF (ß = 0.08;
p < 0.001) scores (Table 2). We found that increasing
novel Medical Index score was significantly associated
with worsening SF-36 PF scores (ß = -0.03; p = 0.002),
SF-36 BP (ß = -0.04; p < 0.001) and a non-significant
trend for worse WOMAC PF scores (ß = 0.02; p = 0.11)
(Table 2). Worsening of the local musculoskeletal index
score (a measure of lower extremity and spine comor-
bidity) correlated significantly with worsening SF-36 PF
(ß = -0.05; p = 0.001), SF-36 BP (ß = -0.04; p = 0.03) and
Fig. 3 X-axis shows the time since TKA, including the baseline post-
operative score at 6–12 months post-index TKA and the subsequent
12–24 month intervals. The Y-axis shows SF-36 physical function (PF)
and bodily pain (BP) subscale scores, which are out of 100 points,
with 0 being the worst score and 100 being the best score
Fig. 1 Post-operative interval was 6–12 months post-index TKA and
subsequent intervals were 12–24 months long. The intervals were
determined based on the time of QOL (SF-36 and WOMAC)
assessment, so that comorbidity scores in the study period prior
could be correlated with the QOL scores
Fig. 2 X-axis shows the time since TKA, including the baseline post-
operative score at 6–12 months post-index TKA and the subsequent
12–24 month intervals. The Y-axis shows WOMAC pain and physical
function (PF) scores, which are out of 100 points, with 0 being the
best score and 100 being the worst score
Fig. 4 X-axis shows both pre-operative and the post-operative
periods since TKA, including the baseline post-operative score at
6–12 months post-index TKA and the subsequent 12–24 month
intervals. The Y-axis shows WOMAC pain and physical function (PF)
subscale scores and SF-36 PF and bodily pain (BP) subscale scores,
which are out of 100 points. On WOMAC, 0 is the best score and
100, the worst score; on SF-36, 0 is the worst and 100, the best score
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WOMAC PF (ß = 0.06; p = 0.01) (Table 2). The TKA-
related index was not associated with worsening any of
the WOMAC or SF36 domain scores. Sensitivity ana-
lysis that excluded the single female subject led to no
change in interpretation of any of these analyses.
Discussion
TKA is the most common arthroplasty procedure world-
wide and its utilization is increasing rapidly [1, 2].
Therefore, it is important to understand the variability
in TKA outcomes. We developed and tested a novel med-
ical/surgical comorbidity index, the Minnesota Arthro-
plasty Comorbidity Index (MACI). MACI took into
account a greater number of comorbidities as compared
to the Charlson index, weighted severity of conditions not
only presence (medical index subscale) and included local
musculoskeletal index and TKA-related index subscales.
We examined the longitudinal association of medical co-
morbidity, local musculoskeletal comorbidity and index
TKA-related morbidity with worsening of pain and func-
tion post-TKA.
As expected and has been shown previously, pain and
function scores improved dramatically from pre-operative
to the post-operative interval. Most, but not all these gains
persisted during intermediate-long post-TKA mean
follow-up of 4.9 years post-operatively (range, 1.3–
11.4 years). We found that medical and local musculoskel-
etal comorbidity in the post-TKA period were associated
with gradual worsening of function and pain outcomes
post-TKA, after a striking initial improvement with TKA,
as demonstrated previously with observational studies.
Several findings merit further discussion.
A few previous studies have reported that pre-
operative comorbidity predicts short-term or very short-
term post-arthroplasty outcomes. SooHoo et al. found
that the preoperative Charlson score predicted several
short-term measures including 90-day readmission
postoperatively [12]. Weaver et al. found that in 11,710
veterans with TKA, higher preoperative Deyo-Charlson
score (modified version) correlated with longer length of
stay and complications 30-days postoperatively [30]. In a
study of relatively healthy Australian patients undergo-
ing total hip or knee arthroplasty, baseline individual co-
morbidity was predictive of change in SF36 physical
domain score from the pre- to post-operative period 12-
months post-arthroplasty [31]. A previous study showed
that SF36 and WOMAC scores declined gradually over
the next several years in a study of 551 TKA patients,
after an initial post-operative improvement [7]. This de-
cline correlated with pre-operative baseline comorbidity
[32]. What we don’t know, however, is whether an in-
crease in comorbidity through time correlates with the
decline in SF36 and WOMAC scores post-TKA. Our
study advances knowledge by examining the association
of change in comorbidity longitudinally after primary
TKA long-term with pain and function outcomes post-
TKA. In our study, we examined change in comorbidity
post-operatively over time, and examined that as the pre-
dictor of pain and function in subsequent periods of ob-
servation. We found that increasing comorbidity post-
TKA was significantly associated with future worsening of
pain and physical function after primary TKA.
Our findings must be compared to a cross-sectional
study done previously on this topic. Dunbar et al. per-
formed a cross-sectional survey 6.7 years post-TKA pa-
tients, and used the modified patient-reported Charnley
Classification [33]. The Class C patients (unilateral TKA
and remote arthritis and/or a medical condition that
affected their ability to ambulate) had statistically signifi-
cantly worse QOL scores demonstrating that a simplified
measure of comorbidity correlated with a decline in pa-
tients’ QOL. The cross-sectional study could not address
this relationship beyond a correlation, since there was
only one measurement post-TKA and both comorbidity
Table 2 Beta-coefficients (ß) and p-values for association between post-operative comorbidity measures and the pain and function
measures post-TKA
Coefficient (95 % CI); p-value

























p = 0.03 (-
Not calculable









SF-36, Short Form 36; WOMAC, Western Ontario McMaster Universities Osteoarthritis index
Significant p-values are in bold
*estimate not reliable, since model fit wasn’t good and the model did not converge
*index, novel medical/surgical comorbidity severity index
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and QOL were examined at the same time. Our study
extends these findings of association of post-TKA co-
morbidity with post-TKA outcomes, by studying them
longitudinally for the first time, controlling for baseline
post-operative pain/function and other confounders,
assessing the worsening or comorbidity in periods prior
to the assessment of pain and function and using mul-
tiple measures of comorbidity. These findings are im-
portant for several reasons.
The clinical relevance of our study findings is that in-
creasing comorbidity in post-TKA years might explain
declining pain and function outcomes in patient sub-
groups in the years after TKA. Surgeons and patients
should discuss this during the informed consent process,
so that expectations are realistic and patients are
empowered with this information. Close monitoring and
early intervention to treat new/worsening comorbidities
might help in reducing the impact of comorbidities on
pain and function outcomes in the long-term follow-up
post-TKA.
Instead of a more simplified measure as described
above, we used two weighted measures of comorbidity
in our study, the Charlson index, and our novel arthro-
plasty comorbidity severity index. The method of meas-
uring and reporting comorbidities in previous studies
varies significantly. Many comorbidity indices tabulate
the comorbidities as a single score with a sum. Studies
commonly stratify patient comorbidity sum as dichot-
omous variable, e.g. <4 vs. 4 or more comorbidities [34].
The summation and stratification methods, however, do
not account for the severity of various illnesses. To ad-
dress this issue, weighted, validated comorbidity mea-
sures have been created, the best known of which is the
Charlson index [22, 35]. Charlson index correlates with
mortality, hospital readmission, length of stay, post-
operative complications, progression-free survival in
cancer patients, and disability [35, 36]. It has been vali-
dated in various conditions, e.g., pneumonia, heart dis-
ease, spine surgery and amputation [36].
In this study, we explored the relationship between
comorbidity and postoperative worsening of QOL mea-
sures. We examined a more comprehensive spectrum of
comorbidities than the Charlson index by creating a
novel medical/surgical comorbidity index focusing on
common comorbidities of TKA patients, which con-
sisted of three component subscales: medical, local mus-
culoskeletal (lower extremity and spine morbidity), and
TKA-related comorbidities (e.g. problems with the TKA
itself ). Our medical/surgical index “medical” subscale
examined 25 common comorbidity categories compared
to 13 in the Charlson index, and while there is some
overlap, we included several more common diagnoses in
the ambulatory patient populations such as those under-
going TKA (e.g. hypertension), rather than more severe
(but much less common) diagnoses as in the Charlson
index (e.g. AIDS or “second metastatic solid tumor”);
the score ranges 0-47. We also included several diagno-
ses of a more function-limiting nature, such as hearing
and vision problems or alcohol abuse. We found that,
both the Charlson Index and our “medical” subscale
score from the novel index correlated with worsening
SF36 PF and WOMAC PF. Future studies should com-
pare their discriminative abilities for TKA outcomes to
understand how to best use these measures in arthro-
plasty patient populations.
Interestingly, our local musculoskeletal index subscale
score also correlated significantly with SF36 PF and
WOMAC PF. This index included opposite knee, hip,
and spine arthritis, as well as local problems such as
neuropathy and vascular disease. This suggests that
lower extremity and spine issues, though localized,
are important determinants of lower extremity as well
as global physical function. Not surprisingly, studies
have shown that ipsilateral hip arthritis/pain, low back
pain, and contralateral knee arthritis/pain might con-
tribute to index knee pain [37–40]. And because the
non-overlapping TKA-related Index included all
TKA-related problems such as loosening or infection,
this finding the association of local musculoskeletal
index subscale score with SF36 PF and WOMAC
PF cannot be attributed to the arthroplasty itself.
We also found that patients with worsening local mus-
culoskeletal index subscale score had more pain in the
subsequent periods post-operatively, indicated by a sig-
nificant association with SF-36 pain scores. Pain corre-
lates with worse functional outcome [41]. Post-TKA
pain is likely multifactorial, related to more than just the
index knee replacement. Increasing comorbidity post-
TKA may interfere with optimal rehabilitation leading to
suboptimal recovery and residual pain and functional
limitation. It remains to be seen whether targeted pain
control and rehabilitation protocols, and optimal peri-
operative management of comorbid conditions can im-
pact post-TKA pain and function outcomes.
Our study has some limitations. We had a relatively
small sample size of 124 patients, of which 123 were
men. We considered limiting the analyses to only men,
but decided to analyze the entire sample, since it makes
our findings more representative of the entire VA patient
population (95–99 % men and 1–5 % women), not just
male veterans. However, we conducted sensitivity ana-
lyses limited to men, which had the same conclusions as
the total cohort (as expected). We controlled for age,
length of time since surgery, and baseline QOL values,
but not for other factors. Some patients, for example,
had undergone only unilateral TKA, while others had
(either before or after the index surgery) undergone sec-
ond TKAs on the opposite knee. This could have
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impacted the pain and function scores, particularly in
patients who had contralateral arthritis but had not had
a contralateral TKA; it would be interesting to explore
this relationship. We did, however, attempt to control
for this by measuring lower-extremity-related comorbid-
ity as described above. Our patients had been enrolled
in three different studies, two randomized and one co-
hort, which may have introduced sample heterogeneity
and we were not able to control for it. The mean
follow-up interval prior to each assessment was 12–
20 months; while slight differences in time-periods can
lead to some heterogeneity in parameter estimates, we
used a repeated measures mixed model linear regres-
sion and comorbidity assessments were performed for
the period prior to each QOL assessment, partially ac-
counting for this.
Comorbidities were abstracted by a physician’s chart
review of their documentation in health care provider
notes. The accuracy of this approach of comorbidity as-
sessment in a retrospective study can not be assessed
due to the absence of a gold standard, such as patient
examination in a prospective cohort study. Despite
suspected under-documentation of some comorbidities
(especially psychological), we suspect that this method
of capturing comorbidity may be more accurate than
capturing diagnostic codes for comorbidity from admin-
istrative databases. Lastly, our newly developed scale is
not validated as yet; test of reliability and several other
aspects of validity are needed before any further use of
the MACI scale. However, additional value over the
existing comorbidity scales wasn’t evident in this study
cohort. It is possible that this scale may be more relevant
for patients undergoing revision arthroplasty or other
joint procedures.
Our study has several strengths. First, our population
was well suited to this investigation. Medical comorbidi-
ties are prevalent in the veteran population, since 72 %
of VA patients have at least one chronic condition [37].
This is significantly higher than the 47 % of Americans
overall with at least one chronic condition [38]. We per-
formed a complete review of both inpatient and out-
patient records. Zhang et al. reported that compared to
a look-back period of 1 year of inpatient data, a longer
look-back period using multiple sources of data (2 years
of inpatient plus 1 year of outpatient) significantly im-
proved the mortality prediction of the Charlson index
[39]. We reviewed more data than this in our patients,
with an average look-back period of 10.5 years (range
2.8–33.8, SD 3.26 years), examined a long-period for
assessing baseline comorbidity. This is a longer follow-
up than in many post-arthroplasty studies of comorbid-
ity, which mostly ranged from 30 days to 2 years [9, 30,
34, 40, 42, 43]. In comparison to certain physician-
derived scores such as the Knee Society Score, which
requires a surgeon’s assessment, [44] we used validated,
patient self-reported instruments (the WOMAC and
SF36) to measure post-TKA outcomes. In TKA patients,
WOMAC may have a bigger effect size and overall re-
sponsiveness than generic surveys [45] such as SF-36
and better correlate with knee-specific complaints [46].
Conclusions
In conclusion, we used validated measures of comorbid-
ity [22, 23], and pain/function/QOL outcomes, the
WOMAC [26] and the SF-36 [47], to measure their rela-
tionship in a post-TKA patient population. Our study
provides further evidence that medical comorbidity load
increased with longer observation times after the pri-
mary TKA. We found that some (but not all) of the ini-
tial gain/improvement of pain and function with primary
TKA was lost over time. We showed that worsening
medical comorbidity over time after the knee arthro-
plasty could explain some of the post-operative decline
in patient outcomes of pain and function. Local muscu-
loskeletal index (including lower extremity, spine etc.)
also influenced pain and function outcomes, in the
intermediate-long term follow-up after primary TKA.
We developed MACI, a novel medical/surgical severity
index for patients with arthroplasty, incorporating med-
ical, local musculoskeletal comorbidity and TKA-related
comorbidity subscales, which will need validation and
further testing.
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